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RESEARCH ARTICLE Open Access
Genetic susceptibility loci of idiopathic
interstitial pneumonia do not represent risk
for systemic sclerosis: a case control study
in Caucasian patients
Minghua Wu1* , Shervin Assassi1, Gloria A. Salazar1, Claudia Pedroza2, Olga Y. Gorlova3, Wei V. Chen3,
Julio Charles1, Miranda L. Taing1, Kelley Liao1, Fredrick M. Wigley4, Laura K. Hummers4, Ami A. Shah4,
Monique Hinchcliff5, Dinesh Khanna6, Elena Schiopu6, Kristine Phillips6, Daniel E. Furst7, Virginia Steen8,
Murray Baron9, Marie Hudson9, Xiaodong Zhou1, Janet Pope10, Niall Jones11, Peter Docherty12, Nader A. Khalidi13,
David Robinson14, Robert W. Simms15, Richard M. Silver16, Tracy M. Frech17, Barri J. Fessler18, Marvin J. Fritzler19,
Jerry A. Molitor20, Barbara M. Segal20, Malahat Movahedian1, Javier Martín21, John Varga5 and Maureen D. Mayes1
Abstract
Background: Systemic sclerosis (SSc)-related interstitial lung disease (ILD) has phenotypic similarities to lung
involvement in idiopathic interstitial pneumonia (IIP). We aimed to assess whether genetic susceptibility loci
recently identified in the large IIP genome-wide association studies (GWASs) were also risk loci for SSc overall or
severity of ILD in SSc.
Methods: A total of 2571 SSc patients and 4500 healthy controls were investigated from the US discovery GWAS
and additional US replication cohorts. Thirteen IIP-related selected single nucleotide polymorphisms (SNPs) were
genotyped and analyzed for their association with SSc.
Results: We found an association of SSc with the SNP rs6793295 in the LRRC34 gene (OR = 1.14, CI 95 % 1.03 to
1.25, p value = 0.009) and rs11191865 in the OBFC1 gene (OR = 1.09, CI 95 % 1.00 to 1.19, p value = 0.043) in the
discovery cohort. Additionally, rs7934606 in MUC2 (OR = 1.24, CI 95 % 1.01 to 1.52, p value = 0.037) was associated
with SSc-ILD defined by imaging. However, these associations failed to replicate in the validation cohort.
Furthermore, SNPs rs2076295 in DSP (β = -2.29, CI 95 % -3.85 to -0.74, p value = 0.004) rs17690703 in SPPL2C
(β = 2.04, CI 95 % 0.21 to 3.88, p value = 0.029) and rs1981997 in MAPT (β = 2.26, CI 95 % 0.35 to 4.17, p value = 0.02)
were associated with percent predicted forced vital capacity (FVC%) even after adjusting for the anti-topoisomerase
(ATA)-positive subset. However, these associations also did not replicate in the validation cohort.
Conclusions: Our results add new evidence that SSc and SSc-related ILD are genetically distinct from IIP, although
they share phenotypic similarities.
Keywords: Idiopathic interstitial pneumonia (IIP), SSc-ILD, Genetic susceptibility
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Background
Systemic sclerosis or scleroderma (SSc) is a complex auto-
immune disease characterized by vasculopathy, autoanti-
body production and fibrosis in the skin and internal
organs. The etiology of SSc remains unknown; effective
treatments that target the underlying pathophysiology of
SSc are unavailable and the disease-related mortality
remains high [1]. Specifically, pulmonary fibrosis and pul-
monary arterial hypertension (PAH) account for the ma-
jority of disease-related deaths in SSc [2]. SSc-associated
interstitial lung disease (SSc-ILD) is usually characterized
by a histologic pattern of nonspecific interstitial pneumo-
nia (NSIP) or, less frequently, usual interstitial pneumonia
(UIP). SSc-ILD has clinical and radiologic similarities to
idiopathic interstitial pneumonia (IIP). A polymorphism in
the MUC5B promoter region was strongly associated with
familial and idiopathic pulmonary fibrosis (IPF; the most
common IIP type) [3], but it has not been found to be a
susceptibility locus for SSc or SSc-associated interstitial
lung disease (SSc-ILD) [4–6].
Recently, large genome-wide association studies (GWASs)
in fibrotic IIP (n = 1616 patients) and IPF (n = 542 pa-
tients and two validation cohorts n = 544 and n = 324)
identified/confirmed susceptibility single nucleotide poly-
morphisms (SNPs) in TERT, AZGP1, MUC2, IVD, DSP,
MAPT, DPP9, LRRC34, FAM13A, OBFC1, CSMD1,
ATP11A [7] and TOLLIP, MDGA2, SPPL2C [8]. Given the
clinical and radiologic similarities between SSc-ILD and
IIP, we examined the association of the 13 SNPs among
the listed genes, identified in the above IIP and IPF
GWASs [7, 8] (TOLLIP and MDGA2 genes were excluded
because the related SNPs were not present on the Illumina
BeadChip utilized in SSc GWAS) with SSc as a single dis-
ease entity, with SSc-ILD by imaging, or SSc-ILD severity
(as determined by percent predicted forced vital capacity
(FVC%)) in two large SSc patient samples.
Methods
Study population
Two non-Hispanic white populations (discovery and
replication cohorts) were investigated. For the discovery
cohort, we utilized data from our previously published
SSc GWAS study consisting of 1486 SSc cases (patients
from the US) and 3477 unaffected race- and ethnicity-
matched controls [9]. Selected polymorphisms were ge-
notyped in an independent replication cohort consisting
of 1085 additional SSc cases (patients from the US and
Canada) and 1023 additional unaffected controls. Patients
were recruited at the University of Texas – Houston and
from the following sites: the participating Canadian
Scleroderma Research Group (CSRG) sites, University
of California Los Angeles, University of Michigan,
Georgetown University, Boston University, Medical Univer-
sity of South Carolina, Johns Hopkins University, University
of Utah, Northwestern University, University of Alabama at
Birmingham and University of Minnesota. All patients
were enrolled in the National Scleroderma Family
Registry and DNA Repository. All patients with SSc ful-
filled the 1980 American College of Rheumatology clas-
sification criteria for SSc or had at least three of the
five CREST (Calcinosis, Raynaud’s phenomenon, Esopha-
geal dysmotility, Sclerodactyly, Telangiectasias) features
(Table 1).
The genotypes of unaffected controls for the discovery
cohort were obtained from the Cancer Genetic Markers of
Susceptibility (CGEMS; non-cancer healthy controls) stud-
ies and Illumina iControlDB database (www.illumina.com/
iControlDB, Illumina, San Diego, CA, USA). The un-
affected controls for the replication cohort were recruited
through a nationwide effort by the Scleroderma Family
Registry and DNA Repository.
Collection of blood samples and clinical information
from case and control subjects was undertaken with fully
informed consent and relevant ethical review board ap-
proval from each contributing center in accordance with
the tenets of the Declaration of Helsinki.
SNP selection and genotyping assay
In the discovery cohort, genotyping was performed using
the Illumina Bead-Array GWAS platform. Specifically, pa-
tients were genotyped using Illumina Human 610-Quad
BeadChip and controls were genotyped on Illumina
Hap550K-BeadChip [9]. The 13 single nucleotide polymor-
phisms (SNPs) identified/confirmed to be associated with
IIP [7], rs2736100 (TERT), rs2076295 (DSP), rs4727443
(AZGP1), rs7934606 (MUC2), rs2034650 (IVD), rs1981997
(MAPT), rs12610495 (DPP9), rs6793295 (LRRC34),
rs2609255 (FAM13A), rs11191865 (OBFC1), rs1278769
(ATP11A), rs1379326 (CSMD1) and an additional SNP
rs17690703 (SPPL2C) [8], were investigated in the discovery
cohort. We also investigated association of 13 SNPs with
anti-topoisomerase 1 antibody (ATA) and anti-centromere
Table 1 Demographic and clinical features of SSc patients in
the discovery and replication cohorts
Discovery (n = 1486) Replication (n = 1085)
Female 1307 (88.0 %) 934 (86.1 %)
Mean age ± years 54.5 ± 12.9 y 56.1 ± 12.8 y
Diffuse SSc 505 (34.0 %) 403 (37.1 %)
Disease duration 10.1 ± 8.7 y 10.9 ± 9.6 y
ACA 425 (28.6 %) 340 (31.3 %)
ATA 238 (16.0 %) 180 (16.6 %)
SSc-ILD
Yes 185 (65.6 %) 313 (61.9 %)
No 97 (34.4 %) 193 (38.1 %)
ACA anti-centromere antibody, ATA anti-topoisomerase 1 antibody, SSc systemic
sclerosis, ILD interstitial lung disease
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antibody (ACA) positive subgroup patients. The SNPs
reaching a nominal level of significance (p < 0.05) in the
discovery cohort (rs6793295 and rs11191865) were geno-
typed in the replication cohort using TaqMan allele dis-
crimination assays in a 7900HT fast real-time PCR system
(Applied Biosystems, Foster City, CA, USA).
SSc-ILD and severity of SSc-ILD
We also investigated the association of the above SNPs
with SSc-ILD by imaging. We compared the frequency
of the above SNPs in patients with SSc-ILD to un-
affected controls. SSc-ILD was defined by chest high-
resolution computed tomography (HRCT)/chest X-ray
images. SSc patients (total = 498; n = 185 in the discovery
cohort and n = 313 in the replication cohort) were con-
sidered to have interstitial lung disease (ILD) by imaging
if they had: (1) ground glass opacity or increased inter-
stitial markings on chest HRCT; or (2) increased basilar
reticular marking on chest X-ray (in total, 498 patients,
185 in the discovery cohort and 313 in the replication
cohort had ILD). The number of patients with imaging-
proven ILD is low because HRCT imaging results were
available only n = 212 in the discovery cohort and n =
347 in the replication cohort patients. The case-case
comparison in regard to presence of ILD was compared
by the low number of patients with available HRCT im-
aging in the discovery cohort.
Furthermore, an association with severity of ILD was
investigated. Percent predicted forced vital capacity
(FVC%) (measured in a total of 1954 patients; n = 1072
in the discovery cohort and n = 882 in the replication co-
hort) as a continuous variable was used as a surrogate
for severity of SSc-ILD as this has been demonstrated to
be a validated outcome measure for severity of ILD in
randomized controlled studies of patients with SSc [10].
SNPs reaching the nominal significance level (p < 0.05)
in these two analyses were also genotyped in the replica-
tion cohort (rs7934606, rs2076295, rs17690703 and
rs1981997).
Statistical analysis
We followed the same genetic inheritance modes for
each specific SNP that was utilized in the IIP GWAS [7].
Specifically, all SNPs except for rs1379326 (CSMD1)
were investigated in an additive model. Similar to the IIP
GWAS [7], rs1379326 (CSMD1) was investigated in a re-
cessive model. The additive model corresponds to the
risk or protective effect conferred by the rarer (minor)
allele (0, 1 or 2 copies) as a predictor of phenotypic sta-
tus; and the recessive model corresponds to the effect
conferred by only homozygous status for the rarer allele.
Genotype data quality was verified for each SNP by test-
ing for Hardy-Weinberg equilibrium (HWE). Hardy-
Weinberg equilibrium was assessed by an x2 test or
Fisher’s exact test. None of the included cohorts showed
significant deviation from HWE for all the genotyped
SNPs. Logistic regression that included both patients
and controls was utilized to examine the association of
the above SNPs with SSc overall and SSc-ILD. A linear
regression model was used to investigate the association
of these genetic variants with FVC% predicted (data was
normally distributed) as a continuous variable, among
patients only. FVC% predicted was investigated as a con-
tinuous rather than a dichotomous variable to increase
our power to detect a difference in FVC levels condi-
tional on the genotype. Anti-topoisomerase 1 antibody
(ATA) status was included as a potential confounder in
the multivariable regression model. The combined ana-
lysis of the discovery and the replication cohorts was
performed via a random-effects meta-analysis model.
Results
Discovery cohort
We first investigated whether the 13 IIP-associated poly-
morphisms were associated with risk of SSc overall or
with SSc-ILD. Several SNPs showed nominally significant
associations with SSc in the discovery cohort (Table 2).
Specifically, LRRC34 rs6793295 (OR = 1.14, CI 95 % 1.03
to 1.25, p value = 0.009) and OBFC1 rs11191865 (OR =
1.09, CI 95 % 1.00 to 1.19, p value = 0.043) were associated
with SSc compared to controls (Table 2). There were no
significant associations observed when the SNP frequen-
cies in SSc antibody subgroups (ATA- or ACA-positive
patients) were compared to controls (Table 3).
Next, we investigated the association in the discovery
cohort between the above polymorphisms and SSc-ILD by
imaging or FVC% predicted in order to investigate the
relationship with SSc-ILD presence or severity. We also
performed case-case comparison by presence of ILD with
no ILD in SSc. Interestingly, rs7934606 in MUC2 (OR =
1.24, CI 95 % 1.01 to 1.52, p value = 0.037) was associated
with SSc-ILD by imaging when compared to controls
(Table 4). Furthermore, three polymorphisms DSP
rs2076295 (β = -2.29, CI 95 % -3.85 to -0.74, p value =
0.004) SPPL2C rs17690703 (β = 2.04, CI 95 % 0.21 to
3.88, p value = 0.029) and MAPT rs1981997 (β = 2.26,
CI 95 % 0.35 to 4.17, p value = 0.02) were associated
with FVC% predicted (Table 5). Of note, the minor al-
lele (A) of MAPT rs1981997 and (T) of SPPL2C
rs17690703 were associated with higher FVC% pre-
dicted, which is consistent with the IIP GWAS results
with the minor allele being protective in that study
(OR < 1) [7]. Even after adjustment for ATA status, the
above three polymorphisms showed nominally signifi-
cant associations with ILD severity in SSc patients
(Table 5). SPPL2C rs17690703 was associated ILD-SSc
compared to SSc with no ILD as determined by imaging
in the discovery cohort (Table S1 in Additional file 1).
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Replication cohort and combined analysis
We genotyped the samples from the validation set for
the above six SNPs, which either showed nominally sig-
nificant associations (p < 0.05) with risk of SSc overall
(LRRC34 rs6793295 and OBFC1 rs11191865) or with
SSc-ILD (rs7934606 in MUC2) and FVC% predicted
(DSP rs2076295, SPPL2C rs17690703 and MAPT
rs1981997). However, these associations were not found
in the replication cohort (Table 4 and upper part of
Table 6). Contrary to the discovery cohort, MAPT
Table 2 Association between the investigated genotypes in SSc-versus-control comparisons in the discovery cohort
SNP Gene Minor allele* MAF (case)** OR (95 % CI) p value
rs2736100 TERT T 0.50 1.04 (0.95; 1.13)† 0.393
rs2076295 DSP G 0.44 0.96 (0.88; 1.05)† 0.387
rs4727443 AZGP1 A 0.41 1.03 (0.95; 1.13)† 0.487
rs7934606 MUC2 A 0.41 1.08 (0.99; 1.18)† 0.084
rs2034650 IVD G 0.49 1.03 (0.95; 1.13)† 0.458
rs1981997 MAPT A 0.22 0.97 (0.88; 1.08)† 0.636
rs12610495 DPP9 G 0.28 1.00 (0.91; 1.10)† 0.967
rs6793295 LRRC34 C 0.29 1.14 (1.03; 1.25)† 0.009
rs2609255 FAM13A G 0.22 1.01 (0.91; 1.12)† 0.851
rs11191865 OBFC1 G 0.52 1.09 (1.00; 1.19)† 0.043
rs1278769 ATP11A A 0.24 0.95 (0.86; 1.06)† 0.365
rs1379326 CSMD1 G 0.26 0.86 (0.69; 1.08)‡ 0.199
rs17690703 SPPL2C T 0.26 1.03 (0.95; 1.11) 0.546
Gene names: TERT: telomerase reverse transcriptase; DSP: desmoplakin; AZGP1: alpha-2-glycoprotein 1, zinc-binding; MUC2: mucin 2; IVD: isovaleryl-CoA dehydrogenase;
MAPT: microtubule-associated protein tau; DPP9: dipeptidyl-peptidase 9; LRRC34: leucine-rich repeat-containing 34; FAMI3A: family with sequence similarity 13, member A;
OBFC1: oligonucleotide/oligosaccharide-binding fold containing 1; ATP11A: ATPase, class VI, type 11A; CSMD1: CUB and Sushi multiple domains 1; SPPL2C: signal peptide
peptidase-like 2C
SSc systemic sclerosis, SNP single nucleotide polymorphism, MAF minor allele frequency
*The minor allele is defined as the minor allele in the combined case and control group; **MAF is defined as the minor allele frequency in cases and controls;
†Odds ratio for the minor allele in the additive model; ‡Odds ratio based on the recessive model
Table 3 Association studies of investigated genotypes in comparison of ATA- or ACA-positive SSc patients to controls in the discov-
ery cohort
ATA (+) ACA (+)
SNP Gene OR (95 % CI) p value OR (95 % CI) p value
rs2736100* TERT 1.01 (0.84; 1.22) 0.881 1.14 (0.99; 1.31) 0.069
rs2076295* DSP 1.01 (0.83; 1.21) 0.945 0.94 (0.82; 1.09) 0.423
rs4727443* AZGP1 1.12 (0.93; 1.36) 0.226 0.96 (0.83; 1.11) 0.609
rs7934606* MUC2 1.00 (0.83; 1.20) 0.992 1.07 (0.93; 1.23) 0.925
rs2034650* IVD 0.99 (0.82; 1.19) 0.915 1.04 (0.90; 1.20) 0.584
rs1981997* MAPT 0.92 (0.73; 1.16) 0.495 1.15 (0.97; 1.36) 0.100
rs12610495* DPP9 0.98 (0.80; 1.20) 0.847 1.05 (0.90; 1.22) 0.572
rs6793295* LRRC34 1.15 (0.94; 1.42) 0.172 1.15 (0.98; 1.35) 0.080
rs2609255* FAMI3A 1.04 (0.83; 1.30) 0.736 1.00 (0.84; 1.19) 1.000
rs11191865* OBFC1 1.21 (1.00; 1.45) 0.048 0.99 (0.86; 1.14) 0.898
rs1278769* ATP11A 1.09 (0.89; 1.35) 0.394 0.96 (0.81; 1.14) 0.650
rs1379326† CSMD1 0.78 (0.46; 1.31) 0.340 0.94 (0.65; 1.36) 0.736
rs17690703 SPPL2C 0.97 (0.76; 1.26) 0.870 1.14 (0.94; 1.38) 0.184
Gene names: TERT: telomerase reverse transcriptase; DSP: desmoplakin; AZGP1: alpha-2-glycoprotein 1, zinc-binding; MUC2: mucin 2; IVD: isovaleryl-CoA dehydro-
genase; MAPT: microtubule-associated protein tau; DPP9: dipeptidyl-peptidase 9; LRRC34: leucine-rich repeat-containing 34; FAMI3A: family with sequence similarity
13, member A; OBFC1: oligonucleotide/oligosaccharide-binding fold containing 1; ATP11A: ATPase, class VI, type 11A; CSMD1: CUB and Sushi multiple domains 1;
SPPL2C: signal peptide peptidase-like 2C
ATA anti-topoisomerase 1 antibody, ACA anti-centromere antibody, SSc systemic sclerosis, SNP single nucleotide polymorphism
*Additive model;,†Recessive model
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rs1981997 (OR = 0.79; CI 95 % 0.68 to 0.91; p value =
0.002) and SPPL2C rs17690703 (OR = 0.64; CI 95 % 0.49
to 0.83; p value = 0.001) were associated with SSc sus-
ceptibility but not with ILD severity in the replication
cohort (Table 6). Furthermore, SPPL2C rs17690703 was
not associated with SSc-ILD when compared to SSc with-
out ILD by imaging in the validation cohort (Table S1 in
Additional file 1).
In the combined discovery and replication cohorts
(lower part of Table 6), only the LRRC34 rs6793295 was
Table 4 Association between the investigated genotypes in SSc-ILD (by imaging) patients compared to controls in the discovery
and replication cohort
SSc-ILD vs control (discovery cohort) SSc-ILD vs control (replication cohort)
SNP (coded allele) Gene OR (95 % CI) p value OR (95 % CI) p value
rs2736100 (T)* TERT 1.14 (0.93; 1.40) 0.199
rs2076295 (G)* DSP 1.13 (0.92; 1.39) 0.243
rs4727443 (A)* AZGP1 0.89 (0.71; 1.10) 0.270
rs7934606 (A)* MUC2 1.24 (1.01; 1.52) 0.037 1.14 (0.81; 1.63) 0.444
rs2034650 (C)* IVD 0.86 (0.70; 1.06) 0.152
rs1981997 (A)* MAPT 0.81 (0.62; 1.06) 0.123
rs12610495 (G)* DPP9 1.17 (0.93; 1.46) 0.179
rs6793295 (C)* LRRC34 1.02 (0.80; 1.30) 0.863
rs2609255 (G)* FAMI3A 0.99 (0.77; 1.27) 0.919
rs11191865 (G)* OBFC1 1.08 (0.87; 1.32) 0.496
rs1278769 (A)* ATP11A 1.00 (0.79; 1.28) 0.987
rs1379326 (G)† CSMD1 0.68 (0.37; 1.27) 0.224
rs17690703 (T)* SPPL2C 1.23 (0.87; 1.72) 0.238
Gene names: TERT: telomerase reverse transcriptase; DSP: desmoplakin; AZGP1: alpha-2-glycoprotein 1, zinc-binding; MUC2: mucin 2; IVD: isovaleryl-CoA dehydro-
genase; MAPT: microtubule-associated protein tau; DPP9: dipeptidyl-peptidase 9; LRRC34: leucine-rich repeat-containing 34; FAMI3A: family with sequence similarity
13, member A; OBFC1: oligonucleotide/oligosaccharide-binding fold containing 1; ATP11A: ATPase, class VI, type 11A; CSMD1: CUB and Sushi multiple domains 1;
SPPL2C: signal peptide peptidase-like 2C
SSc systemic sclerosis, ILD interstitial lung disease, SNP single nucleotide polymorphism
*Additive model; †Recessive model
Table 5 Association between the investigated genotypes and FVC% predicted in SSc patients in the discovery cohort
FVC% FVC% (adjusted for ATA status)
SNP (Coded allele) Gene β (95 % CI) p value β (95 % CI) p value
rs2736100 (T)* TERT 0.51 (-1.04; 2.05) 0.521 0.76 (-0.81; 2.34) 0.343
rs2076295 (G)* DSP −2.29 (-3.85; -0.74) 0.004 −2.52 (-4.09; -0.95) 0.002
rs4727443 (A)* AZGP1 −0.27 (-1.85; 1.32) 0.742 0.08 (-1.53; 1.70) 0.919
rs7934606 (A)* MUC2 −0.55 (-2.16; 1.05) 0.499 −0.75 (-2.37; 0.86) 0.360
rs2034650 (C)* IVD 0.67 (-0.90; 2.25) 0.402 0.37 (-1.22; 1.97) 0.646
rs1981997 (A)* MAPT 2.26 (0.35; 4.17) 0.020 3.19 (1.23; 5.14) 0.001
rs12610495 (G)* DPP9 0.57 (-1.18; 2.32) 0.523 1.05 (-0.72; 2.82) 0.246
rs6793295 (C)* LRRC34 −0.46 (-2.19;1.27) 0.599 −1.05 (-2.82; 0.71) 0.242
rs2609255 (G)* FAMI3A 1.72 (-0.10; 3.55) 0.064 1.61 (-0.18; 3.41) 0.079
rs11191865 (G)* OBFC1 −0.73 (-2.27; 0.82) 0.356 0.02 (-1.55; 1.60) 0.977
rs1278769 (A)* ATP11A −0.62 (-2.45; 1.20) 0.503 −0.74 (-2.60; 1.11) 0.433
rs1379326 (G)† CSMD1 3.35 (-0.84; 7.54) 0.117 3.12 (-1.08; 7.31) 0.145
rs17690703 (T)* SPPL2C 2.04 (0.21; 3.88) 0.029 2.11 (0.30; 3.91) 0.022
Gene names: TERT: telomerase reverse transcriptase; DSP: desmoplakin; AZGP1: alpha-2-glycoprotein 1, zinc-binding; MUC2: mucin 2; IVD: isovaleryl-CoA dehydrogenase;
MAPT: microtubule-associated protein tau; DPP9: dipeptidyl-peptidase 9; LRRC34: leucine-rich repeat-containing 34; FAMI3A: family with sequence similarity 13, member
A; OBFC1: oligonucleotide/oligosaccharide-binding fold containing 1; ATP11A: ATPase, class VI, type 11A; CSMD1: CUB and Sushi multiple domains 1; SPPL2C: signal
peptide peptidase-like 2C
FVC% percent predicted forced vital capacity, SSc systemic sclerosis, ATA anti-topoisomerase 1 antibody, SNP single nucleotide polymorphism
*Additive model; †Recessive model
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associated with risk of SSc overall (OR = 1.11; CI 95 %
1.03 to 1.2; p value = 0.01). However, the observed sig-
nificance level was not stronger in the combined cohort
than in the discovery cohort and this association did not
withstand correction for multiple comparisons. Specific-
ally, the p value = 0.13 in the combined cohort after
Bonferroni correction for multiple comparisons. Fur-
thermore, LRRC34 rs6793295 was not associated with
FVC% predicted in the combined cohort. SPPL2C
rs17690703 was associated with FVC% predicted in the
combined cohort but not after ATA adjustment or with
overall SSc risk (Table 6). The observed association of
SPPL2C rs17690703 with FVC% did not withstand cor-
rection for multiple comparison (pcorr = 0.078).
Discussion
The aim of this study was to assess genetic components
of SSc and SSc-related ILD, specifically to determine if
SSc-ILD and IIP share common genetic risk factors. We
analyzed 13 SNPs which showed robust association with
IIP in a previous GWAS report [7, 8]. However, we failed
to replicate these associations with SSc or SSc-related
ILD in a large North American cohort.
Interstitial lung disease (ILD) is the most common
pulmonary manifestation in patients with SSc [11] and is
the most frequent cause of SSc disease-related death
[12]. ILD occurs with greater frequency and increased
severity in patients with diffuse cutaneous SSc (dc-SSc)
and in ATA-positive patients. In SSc-ILD, loss of lung
function and extent of fibrosis are the most important
prognostic factors. It is known that genetic factors con-
tribute not only to SSc susceptibility, but also to
predisposition to SSc clinical phenotypes including dis-
ease type (limited versus diffuse cutaneous disease) and
autoantibody status [13]. Recently, several lines of evi-
dence have suggested that, even though SSc-ILD has
phenotypic similarities to IIP, the genetic risk factors for
these two conditions are quite different. For example the
MUC5B promoter region polymorphism (rs868903),
which was strongly associated with familial and idio-
pathic pulmonary fibrosis [3, 7], was not identified as a
susceptibility locus for SSc or SSc–associated intersti-
tial lung disease [4–6]. In addition, the two large SSc
GWAS reports (each with independent discovery and
validation cohorts) identified the major histocompati-
bility complex (MHC) class II region as being the most
strongly associated region with SSc [9, 14], whereas
MHC loci were not found to be risk factors in the IIP
GWAS [7].
The present study has some limitations. In our study,
only a subgroup of SSc patients had undergone HRCT.
We performed a case-case comparison in regard to pres-
ence of SSc-ILD versus no SSc-ILD in the low number
of patients because HRCT results were not available in
the remainder of patients. The genotype results for TOL-
LIP and MDGA2 genes were not available on our GWAS
platform and could not be investigated. Furthermore,
this is a cross-sectional study, thus, we cannot examine
whether the investigated genetic loci have predictive sig-
nificance for ILD progression. However, mean disease
duration of this study was more than 10 years and most
of the SSc-ILD cases had been already established.
Therefore, we believe the cross-sectional FVC% is a rea-
sonable surrogate for severity of ILD.
Table 6 Association analysis of investigated genotypes in SSc versus control comparison as well as FVC% in the replication and
combined cohorts
Allele frequency FVC% FVC%–adjusted for ATA
SNPs Gene OR (95 % CI) p value β (95 % CI) p value β (95 % CI) p value
Replication rs2076295 (G)† DSP 0.93 (0.82; 1.05) 0.252 0.32 (-1.49; 2.13) 0.729 0.39 (-1.40; 2.17) 0.671
rs1981997 (A)† MAPT 0.79 (0.68; 0.91) 0.002 0.15 (-2.05; 2.35) 0.894 −0.01 (-2.17; 2.15) 0.994
rs6793295 (C)† LRRC34 1.06 (0.92; 1.21) 0.435 −0.54 (-2.53;1.45) 0.593 −0.55 (-2.51; 1.41) 0.581
rs11191865 (G)† OBFC1 0.90 (0.80; 1.01) 0.093 −0.34 (-2.11; 1.44) 0.710 −0.30 (-2.05; 1.45) 0.736
rs17690703 (T)† SPPL2C 0.64 (0.49; 0.83) 0.001 2.20 (-1.38; 5.78) 0.227 3.11 (-0.45; 6.66) 0.086
Combined rs2076295 (G)† DSP 0.95 (0.89; 1.02) 0.171 −1.02 (-3.58; 1.54) 0.579 −1.07 (-3.94; 1.80) 0.079
rs1981997 (A)† MAPT 0.89 (0.78; 1.02) 0.091 1.26 (-0.81; 3.32) 0.445 1.59 (-1.56; 4.74) 0.503
rs6793295 (C)† LRRC34 1.11 (1.03; 1.20) 0.010 −0.50 (-1.80; 0.81) 0.590 −0.81 (-2.12; 0.50) 0.440
rs11191865 (G)† OBFC1 1.01 (0.90; 1.13) 0.912 −0.55 (-1.72; 0.61) 0.524 −0.13 (-1.30; 1.04) 0.868
rs17690703 (T)† SPPL2C 1.04 (0.97; 1.13) 0.221 2.32 (0.68; 3.96) 0.006 −1.03 (-4.67; 2.60) 0.575
Gene names: TERT: telomerase reverse transcriptase; DSP: desmoplakin; AZGP1: alpha-2-glycoprotein 1, zinc-binding; MUC2: mucin 2; IVD: isovaleryl-CoA dehydro-
genase; MAPT: microtubule-associated protein tau; DPP9: dipeptidyl-peptidase 9; LRRC34: leucine-rich repeat-containing 34; FAMI3A: family with sequence similarity
13, member A; OBFC1: oligonucleotide/oligosaccharide-binding fold containing 1; ATP11A: ATPase, class VI, type 11A; CSMD1: CUB and Sushi multiple domains 1;
SPPL2C: signal peptide peptidase-like 2C
SSc systemic sclerosis, FVC % percent predicted forced vital capacity, ATA anti-topoisomerase 1 antibody, SNP single nucleotide polymorphism
†Additive model
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Conclusions
In this study, we confirm that genetic susceptibility loci
for IIP are not risk loci for SSc or severity of SSc-ILD in
two validation SSc cohorts of non-Hispanic white ethnic
background. Our findings and those of previous genetic
susceptibility studies in SSc [15] implicate pathways in
innate and adaptive immunity, whereas susceptibility loci
for IIP relate to epithelial cell injury/dysfunction and ab-
normal wound healing [16]. Future challenges will be to
identify the functional relevance of these variants for the
final common pathway that results in the phenotype of
fibrotic lung disease. This study represents an important
step forward toward a better understanding of the com-
plex genetic association of SSc particularly with lung in-
volvement. We add new evidence that SSc and SSc-ILD
are genetically distinct from IIP.
Additional file
Additional file 1: Table S1. Association between the investigated
genotypes in SSc-ILD (by imaging) patients compared to SSc-no ILD
(by imaging) in the discovery and replication cohort. (DOCX 19 kb)
Abbreviations
ACA: Anti-centromere antibody; ATA: Anti-topoisomerase 1 antibody;
CGEMS: Cancer Genetic Markers of Susceptibility; CREST: Calcinosis, Raynaud’s
phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasias;
dcSSc: Diffuse cutaneous SSc; FVC%: Percent predicted forced vital capacity;
GWAS: Genome-wide association study; HRCT: High-resolution computed
tomography; HWE: Hardy-Weinberg equilibrium; IIP: Idiopathic interstitial
pneumonia; ILD: Interstitial lung disease; IPF: Idiopathic pulmonary fibrosis;
MHC: Major histocompatibility complex; NSIP: Nonspecific interstitial
pneumonia; PAH: Pulmonary arterial hypertension; SNP: Single nucleotide
polymorphisms; SSc: Systemic sclerosis; SSc-ILD: SSc-associated interstitial
lung disease; UIP: Usual interstitial pneumonia.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MW, SA, JV, and MDM contributed to study conception and design, MW, SA,
GAS, JC, MLT, KL, FMW, LKH, AAS, MH, DK, ES, KP, DEF, VS, MB, MH, XZ, JP, NJ,
PD, NAK, DR, RWS, RMS, TMF, BJF, MJF, JAM, BMS, MM, JM, JV, and MDM
contributed to acquisition of data. MW, SA, GAS, CP, OYG, WVC, JC, MLT, KL,
FMW, LKH, AAS, MH, DK, ES, KP, DEF, VS, MB, MH, XZ, JP, NJ, PD, NAK, DR,
RWS, RMS, TMF, BJF, MJF, JAM, BMS, MM, JM, JV, and MDM contributed to
analysis and interpretation of data. MW had full access to all of the data in
the study and takes responsibility for the integrity of the data and accuracy
of the data analysis. All authors were involved in drafting the manuscript or
revising it critically for important intellectual content, and all authors
approved the final version to be submitted for publication.
Acknowledgements
The authors thank Marilyn Perry and Yuxiao Du for their work as Registry
coordinators and we are grateful for the generous participation of our
subjects. This work was supported by the Scleroderma Foundation New
Investigator Award to Dr. Wu, and by the National Institutes of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Centers of Research Translation (CORT) grant P50AR054144 to Dr. Mayes, NIH
grant K23AR061436 to Dr. Assassi, NIH/NIAMS Scleroderma Family Registry
and DNA Repository grant N01-AR02251 to Dr. Mayes, NIH/NIAMS grant
AR055258 to Dr. Mayes, NIH National Center for Clinical and Translational
Sciences grant 3UL1RR024148, Department of Defense Congressionally
Directed Medical Research Program W81XWH-13-1-0452, Proposal number
PR120687 to Dr. Mayes.
Author details
1Division of Rheumatology and Clinical Immunogenetics, Department of
Internal Medicine, University of Texas McGovern Medical School at Houston,
6431 Fannin Street, Houston, TX 77030, USA. 2Department of Pediatrics, The
University of Texas Mcgovern Medical School at Houston, 6431 Fannin Street,
Houston, TX 77030, USA. 3Department of Community and Family Medicine,
Geisel School of Medicine at Dartmouth, 1 Rope Ferry Road, Hanover, NH
03755, USA. 4Division of Rheumatology, Johns Hopkins University School of
Medicine, 5501 Hopkins Bayview circle, Baltimore, MD 21224, USA. 5Division
of Rheumatology, Northwestern University Feinberg School of Medicine, 240
East Huron Street, Chicago, IL 60611, USA. 6Department of Internal Medicine,
Division of Rheumatology, University of Michigan Health Center, 300 North
Ingalls Street, Ann Arbor, MI 48109, USA. 7Division of Rheumatology,
University of California Los Angeles, 1000 Veterans Avenue, Los Angeles, CA
90024, USA. 8Division of Rheumatology, Georgetown University Medical
Center, 3800 Reservoir Road, Washington, MD 20007, USA. 9Division of
Rheumatology, McGill University, 1650 Cedar Avenue, Montreal, QC H3G 1A4,
Canada. 10Division of Rheumatology, St. Joseph’s Health Care, University of
Western Ontario, 268 Grosvenor Street, London, ON, Canada. 11Division of
Rheumatology, University of Alberta, 11405-87 Avenue, Edmonton, AB T6G
1C9, Canada. 12Division of Rheumatology, Moncton Hospital, 135 MacBeath
Avenue, Moncton, NB E1C 6Z8, Canada. 13Division of Rheumatology,
McMaster University at Hamilton, 1280 Main Street West, Hamilton, ON L8S
4L8, Canada. 14Division of Rheumatology, University of Manitoba, 820
Sherbrook Street, Winnipeg, MB R3A 1R9, Canada. 15Division of
Rheumatology, Boston University School of Medicine, 72 East Concord Street,
Boston, MA 02118, USA. 16Division of Rheumatology, Medical University of
South Carolina, 171 Ashley Avenue, Charleston, SC 29425, USA. 17Division of
Rheumatology, University of Utah, 30 North 1900 East, Salt Lake City, UT
84132, USA. 18Division of Clinical Immunology and Rheumatology, University
of Alabama at Birmingham, 1825 University Boulevard, Birmingham, AB
35294, USA. 19Division of Rheumatology, University of Calgary Cumming
School of Medicine, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada.
20Division of Rheumatology, University of Minnesota, 420 Delaware Street SE,
Minneapolis, MN 55455, USA. 21Instituto de Parasitología y Biomedicina
López-Neyra, Consejo Superior de Investigaciones Cientıficas, C/Ventanilla 11,
18001 Granada, Spain.
Received: 8 July 2015 Accepted: 6 January 2016
References
1. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in
patients with systemic sclerosis over 40 years: a systematic review and
meta-analysis of cohort studies. Rheumatology (Oxford). 2012;51:1017–26.
2. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and
risk factors for death in systemic sclerosis: a study from the EULAR
Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis.
2010;69:1809–15.
3. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, et al.
A common MUC5B promoter polymorphism and pulmonary fibrosis.
N Engl J Med. 2011;364:1503–12.
4. Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, et al.
Mucin 5B promoter polymorphism is associated with idiopathic pulmonary
fibrosis but not with development of lung fibrosis in systemic sclerosis or
sarcoidosis. Thorax. 2013;68:436–41.
5. Borie R, Crestani B, Dieude P, Nunes H, Allanore Y, Kannengiesser C, et al.
The MUC5B variant is associated with idiopathic pulmonary fibrosis but not
with systemic sclerosis interstitial lung disease in the European Caucasian
population. PLoS One. 2013;8:e70621.
6. Peljto AL, Steele MP, Fingerlin TE, Hinchcliff ME, Murphy E, Podlusky S, et al.
The pulmonary fibrosis-associated MUC5B promoter polymorphism does
not influence the development of interstitial pneumonia in systemic
sclerosis. Chest. 2012;142:1584–8.
7. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, et al.
Genome-wide association study identifies multiple susceptibility loci for
pulmonary fibrosis. Nat Genet. 2013;45:613–20.
Wu et al. Arthritis Research & Therapy  (2016) 18:20 Page 7 of 8
8. Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y, et al. Genetic variants
associated with idiopathic pulmonary fibrosis susceptibility and mortality: a
genome-wide association study. Lancet Respir Med. 2013;1:309–17.
9. Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales
R, et al. Genome-wide association study of systemic sclerosis identifies
CD247 as a new susceptibility locus. Nat Genet. 2010;42:426–9.
10. Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, et al.
Systemic sclerosis - continuing progress in developing clinical measures of
response. J Rheumatol. 2007;34:1194–200.
11. Ramirez A, Varga J. Pulmonary arterial hypertension in systemic sclerosis:
clinical manifestations, pathophysiology, evaluation, and management.
Treat Respir Med. 2004;3:339–52.
12. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis,
1972-2002. Ann Rheum Dis. 2007;66:940–4.
13. Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M, et al.
Identification of novel genetic markers associated with clinical phenotypes
of systemic sclerosis through a genome-wide association strategy. PLoS
Genet. 2011;7:e1002178.
14. Allanore Y, Saad M, Dieude P, Avouac J, Distler JH, Amouyel P, et al.
Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci
for systemic sclerosis. PLoS Genet. 2011;7:e1002091.
15. Wu M, Mayes MD. Insights into the genetic basis of systemic sclerosis:
immunity in human disease and in mouse models. Adv Genomics Genet.
2014;4:143–51.
16. Spagnolo P, Grunewald J, du Bois RM. Genetic determinants of pulmonary
fibrosis: evolving concepts. Lancet Respir Med. 2014;2:416–28.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wu et al. Arthritis Research & Therapy  (2016) 18:20 Page 8 of 8
